Stem cells, organoids, and organ-on-a-chip models for personalized in vitro drug testing

IF 6.1 Q1 TOXICOLOGY
Damiën van Berlo , Vivian V.T. Nguyen , Vasiliki Gkouzioti , Kirsten Leineweber , Marianne C. Verhaar , Bas W.M. van Balkom
{"title":"Stem cells, organoids, and organ-on-a-chip models for personalized in vitro drug testing","authors":"Damiën van Berlo ,&nbsp;Vivian V.T. Nguyen ,&nbsp;Vasiliki Gkouzioti ,&nbsp;Kirsten Leineweber ,&nbsp;Marianne C. Verhaar ,&nbsp;Bas W.M. van Balkom","doi":"10.1016/j.cotox.2021.08.006","DOIUrl":null,"url":null,"abstract":"<div><p>Breakthroughs in stem cell biology and microfluidics technology have opened doors to <em>in vitro</em> screening platforms for personalized testing of safety (pharmaceuticals, nutrients, chemicals) and efficacy (pharmaceuticals, nutraceuticals). Major breakthrough technologies include development of induced pluripotent stem cells, the development of induced pluripotent stem cell-derived organoids and adult stem cell-derived organoids, and the generation of organ-on-a-chip and multi-organ-on-a-chip models to mimic human physiology <em>in vitro</em>. These technologies are highly complementary and offer tremendous potential for improved efficiency in drug development and chemical safety testing. In the current review, we will provide an overview of recent advances in <em>in vitro</em> modeling for personalized drug testing based on stem cell and organ-on-a-chip technologies and illustrate how these developments will eventually lead to the replacement of animal testing. Particular focus will be on multi-organ-on-chip human disease models, which have the potential to be the gold standard of the future for the investigation of safety, toxicity, and efficacy of newly developed medicines.</p></div>","PeriodicalId":37736,"journal":{"name":"Current Opinion in Toxicology","volume":"28 ","pages":"Pages 7-14"},"PeriodicalIF":6.1000,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.cotox.2021.08.006","citationCount":"13","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Toxicology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2468202021000413","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"TOXICOLOGY","Score":null,"Total":0}
引用次数: 13

Abstract

Breakthroughs in stem cell biology and microfluidics technology have opened doors to in vitro screening platforms for personalized testing of safety (pharmaceuticals, nutrients, chemicals) and efficacy (pharmaceuticals, nutraceuticals). Major breakthrough technologies include development of induced pluripotent stem cells, the development of induced pluripotent stem cell-derived organoids and adult stem cell-derived organoids, and the generation of organ-on-a-chip and multi-organ-on-a-chip models to mimic human physiology in vitro. These technologies are highly complementary and offer tremendous potential for improved efficiency in drug development and chemical safety testing. In the current review, we will provide an overview of recent advances in in vitro modeling for personalized drug testing based on stem cell and organ-on-a-chip technologies and illustrate how these developments will eventually lead to the replacement of animal testing. Particular focus will be on multi-organ-on-chip human disease models, which have the potential to be the gold standard of the future for the investigation of safety, toxicity, and efficacy of newly developed medicines.

用于个性化体外药物测试的干细胞、类器官和器官芯片模型
干细胞生物学和微流体技术的突破为安全性(药物、营养物质、化学品)和有效性(药物、营养保健品)的个性化测试打开了体外筛选平台的大门。主要突破技术包括诱导多能干细胞的发展,诱导多能干细胞衍生类器官和成体干细胞衍生类器官的发展,以及体外模拟人体生理的器官芯片和多器官芯片模型的产生。这些技术具有很强的互补性,为提高药物开发和化学品安全测试的效率提供了巨大的潜力。在当前的综述中,我们将概述基于干细胞和器官芯片技术的个性化药物测试体外建模的最新进展,并说明这些发展将如何最终导致动物测试的替代。将特别关注芯片上的多器官人类疾病模型,这有可能成为未来研究新开发药物的安全性、毒性和有效性的黄金标准。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Current Opinion in Toxicology
Current Opinion in Toxicology Pharmacology, Toxicology and Pharmaceutics-Toxicology
CiteScore
10.40
自引率
0.00%
发文量
43
期刊介绍: The aims and scope of Current Opinion in Toxicology is to systematically provide the reader with timely and provocative views and opinions of the highest qualified and recognized experts on current advances in selected topics within the field of toxicology. The goal is that Current Opinion in Toxicology will be an invaluable source of information and perspective for researchers, teachers, managers and administrators, policy makers and students. Division of the subject into sections: For this purpose, the scope of Toxicology is divided into six selected high impact themed sections, each of which is reviewed once a year: Mechanistic Toxicology, Metabolic Toxicology, Risk assessment in Toxicology, Genomic Toxicology, Systems Toxicology, Translational Toxicology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信